Ana Jaklenec

前言 新冠之后，mRNA技术的产业问题已经从"能不能快速做出疫苗"转向"能不能稳定、便宜、可及地交付"。冷链是其中最现实的一环。固态化、冻干、微针贴片等方向，本质上都在回答同一个问题：如何让mRNA-LNP从一个高度依赖水相环境的纳米组装体，变成可以运输、储存、再激活的药物产品。 但对mRNA-LNP来说，干燥并不只是“把水拿掉”那么简单。 mRNA疫苗的稳定性由两部分共同决定：一是mRNA分子本身，二是包载它的脂质纳米颗粒。后者并不是一个惰性的载体，而是由可电离脂质、辅助磷脂、胆固醇和PEG脂质共同形成的自组装体系。也正因为是自组装材料，LNP在干燥或后续加工过程中可能发生聚集、坍塌、相态重排，进而改变原有结构特征、载药状态和递送活性。 近日，麻省理工学院Koch研究所Ana Jaklenec和Robert Langer课题组，联合澳大利亚RMIT大学Calum Drummond团队，发表于Advanced Functional Materials的研究“Exploring an Alternative to mRNA Vaccine Cold Chain...

is critical for vision, a healthy immune system, and the normal functioning of organs such as the heart and lungs but deficiency is widespread in many countries. Nearly half (48%) of children in sub-Saharan Africa and 44% in south Asia were deficient in 2013, with over one hundred thousand children’s deaths attributable to vitamin A deficiency.

Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA, USA Department of Anesthesiology, Boston...